On September 9, 2026 Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, reported plans to commence a world-first Phase 1b first-in-human (FIH) study of PRP in February 2027.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The multicenter, open-label study will enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at trial centers across Australia. The two-part design, dose escalation (Part A) followed by dose expansion (Part B), is intended to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of PRP.

Several workstreams are advancing in parallel to support study start:

Manufacturing: GMP manufacture of finished drug product is underway. A small-scale technology transfer run has been completed. Two scale-up runs are scheduled this month, with an engineering run planned for late October. Raw drug substance supply for the PRP formulation is secured after recent audit and vendor qualification processes were successfully completed.
Bio-analytics: PK method validation has commenced. Development of an anti-drug antibody assay is underway, and in-use stability testing of the finished PRP formulation is scheduled.
Regulatory and ethics: Supporting documentation for Human Research Ethics Committee (HREC) submission is in preparation, including the Investigator’s Brochure (IB), a briefing document drawn from the IB, and the clinical trial protocol. Documents will be provided to investigators at Australian trial sites for feasibility assessment ahead of the planned HREC submission in November 2026.
PRP will be administered as a weekly intravenous infusion on Days 1, 8, 15, and 22 of each 28-day cycle. Treatment may continue until a withdrawal criterion is met.

Part A will use a Bayesian Optimal Interval (BOIN) design with backfill (BF-BOIN) and a predefined target dose-limiting toxicity (DLT) probability to identify the maximum tolerated dose (MTD), if reached, and/or up to two recommended doses for optimization and expansion (RDO). Up to five dose levels are planned. Following selection of the RDO(s) in Part A, Part B will further evaluate safety, tolerability, and preliminary antitumor activity in one or more tumor-specific expansion cohorts.

"We are making meaningful progress toward a pivotal milestone for Propanc as we prepare to advance PRP into the clinic," said James Nathanielsz, Chief Executive Officer of Propanc. "Our team is diligently executing planned manufacturing, analytical, and regulatory work required to initiate a world-first Phase 1b first-in-human study of PRP. Our objective is a therapy that can extend survival and improve quality of life for patients with limited remaining options — without the severe toxicities often associated with standard regimens. After years of research, that clinical milestone is now coming into view."

(Press release, Propanc, SEP 9, 2026, View Source [SID1234670673])